» BioTime
By Beth Marie Mole | January 8, 2013
BioTime finalizes a deal to buy Geron’s defunct human embryonic stem cell assets.
0 Comments
Page 1 of 1
View the May 2013 contents.
© 1986-2013 The Scientist